Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cencora, Inc.COR · Entity 2994 | Director | March 05, 2026 | March 09, 2026 |
| DuPont de Nemours, Inc.DD · Entity 3297 | Director | April 28, 2021 | April 30, 2021 |
| INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234 | Chief Executive Officer | March 01, 2024 | March 06, 2024 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres ? Human Health | May 04, 2021 | November 04, 2021 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cencora, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,724 |
Reported balance
After 2026-03-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 557 · Balance 1,724 F1: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant.
DuPont de Nemours, Inc.
Report date April 28, 2021 · Filed April 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,034.4895 |
Reported balance
After 2021-04-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-28 · Grant · Acquired 2,207 · Balance 8,034.4895 F1: Includes acquisition of shares pursuant to dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes acquisition of shares pursuant to dividend reinvestment.
INTERNATIONAL FLAVORS & FRAGRANCES INC
Report date March 01, 2024 · Filed March 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,847 |
Ending reported balance
After 2024-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-01 · Exercise / conversion · Acquired 1,324 · Balance 2,170 F1: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022. F2: The RSUs convert to Common Stock on a one-for-one basis. Row 2 · 2024-03-01 · Tax withholding · Disposed 323 · Balance 1,847 F3: Reflects shares withheld for taxes payable upon the vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,682 |
Reported balance
After 2024-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-01 · Exercise / conversion · Disposed 1,324 · Balance 33,682 F2: The RSUs convert to Common Stock on a one-for-one basis. F1: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022. F4: The RSUs vested on March 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022.
F2: The RSUs convert to Common Stock on a one-for-one basis.
F3: Reflects shares withheld for taxes payable upon the vesting of RSUs.
F4: The RSUs vested on March 1, 2024.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Merck & Co., Inc.
Report date May 04, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 39,479 |
Reported balance
After 2021-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-04 · Grant · Acquired 39,479 · Balance 39,479 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in one installment on 5/4/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in one installment on 5/4/2024.
Revolution Medicines, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,929 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 1,191 · Balance 10,929 F1: Includes 4,080 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $162.99 · Expires 2036-06-18 | Direct | 3,127 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 3,127 · Balance 3,127 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 4,080 restricted stock units.
F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:44 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 3,127 | $0.00 Strike: $162.99 | $0.00 |
DisclosureSEC source: 0001610717-26-000285 · form4.xml · derivative · entry 2 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 3,127 shares Expires 2036-06-18 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:44 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000285 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,929 F1 · balance_after: Includes 4,080 restricted stock units. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:04 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 38,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164224 · ownership.xml · derivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:21 UTC | Cencora, Inc. COR · Entity 2994 | GrantCommon Stock | 557 | $359.28 | $200,118.96 |
DisclosureSEC source: 0001763963-26-000004 · wk-form4_1773087692.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,724 F1 · balance_after: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of the grant. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 10,337 | $0.00 Strike: $37.48 | $0.00 |
DisclosureSEC source: 0001610717-25-000267 · form4.xml · derivative · entry 2 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,337 Underlying: Common Stock · 10,337 shares Expires 2035-06-26 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 2,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000267 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,738 F1 · balance_after: Includes 8,005 Restricted Stock Units. Read SEC document |
| March 11, 2025 Filed Jan 16, 2026 21:12 UTC | Cencora, Inc. COR · Entity 2994 | OtherCommon Stock | 4 | $260.69 | $1,042.77 |
DisclosureSEC source: 0001763963-26-000002 · wk-form5_1768597970.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161 Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:33 UTC | Cencora, Inc. COR · Entity 2994 | GrantCommon Stock | 789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140859-25-000053 · wk-form4_1741638769.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,157 F1 · price: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:03 UTC | Cencora, Inc. COR · Entity 2994 | GrantCommon Stock | 368 | $234.27 | $86,211.36 |
DisclosureSEC source: 0001140859-24-000140 · wk-form4_1730840623.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368 F1 · shares: Grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:34 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 27,744 | $0.00 Strike: $42.48 | $0.00 |
DisclosureSEC source: 0001610717-24-000416 · form4.xml · derivative · entry 2 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,744 Underlying: Common Stock · 27,744 shares Expires 2034-08-05 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of August 5, 2024, subject to the reporting person's continued employment or service relationship with the Company on each such vesting date. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:34 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 6,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000416 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,932 F1 · balance_after: Includes 6,932 restricted stock units. Read SEC document |
| August 05, 2024 Filed Apr 28, 2025 22:27 UTC Amendment | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 26,540 | $0.00 Strike: $42.48 | $0.00 |
DisclosureSEC source: 0001610717-25-000106 · form4.xml · derivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,540 Underlying: Common Stock · 26,540 shares Expires 2034-08-05 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of August 5, 2024, subject to the reporting person's continued employment or service relationship with the Company on each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:06 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionRestricted Stock Units · Derivative | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003735 · doc4.xml · derivative · entry 3 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,682 Underlying: Common Stock · 1,324 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F1 · shares: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022. F2 · price: The RSUs convert to Common Stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs vested on March 1, 2024. F4 · derivative.expiration_date: The RSUs vested on March 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:06 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Tax withholdingCommon Stock | 323 | $75.88 | $24,509.24 |
DisclosureSEC source: 0001225208-24-003735 · doc4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,847 F3 · shares: Reflects shares withheld for taxes payable upon the vesting of RSUs. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:06 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionCommon Stock | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003735 · doc4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on March 1, 2022. F2 · price: The RSUs convert to Common Stock on a one-for-one basis. Read SEC document |
| May 03, 2023 Filed May 5, 2023 23:44 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 35,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005547 · doc4.xml · derivative · entry 2 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,006 Underlying: Common Stock · 35,006 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · derivative.exercise_date: RSUs vest in three equal tranches with respect to 11,668 shares of Common Stock on each of May 3, 2024, 2025 and 2026, subject to continued employment with IFF. F2 · derivative.expiration_date: RSUs vest in three equal tranches with respect to 11,668 shares of Common Stock on each of May 3, 2024, 2025 and 2026, subject to continued employment with IFF. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:38 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionRestricted Deferred Stock Units · Derivative | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-003149 · doc4.xml · derivative · entry 3 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,296 Underlying: Common Stock · 1,323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The DSUs convert to Common Stock on a one-for-one basis. F1 · shares: Reflects vesting and settlement of Deferred Restricted Stock Units ("DSUs") granted on March 1, 2022. F2 · price: The DSUs convert to Common Stock on a one-for-one basis. F4 · derivative.exercise_date: The DSUs vested on March 1, 2023. F4 · derivative.expiration_date: The DSUs vested on March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:38 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Tax withholdingCommon Stock | 477 | $91.64 | $43,712.28 |
DisclosureSEC source: 0001225208-23-003149 · doc4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846 F3 · shares: Reflects shares withheld for taxes payable upon the vesting of DSUs. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:38 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Exercise / conversionCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-003149 · doc4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting and settlement of Deferred Restricted Stock Units ("DSUs") granted on March 1, 2022. F2 · price: The DSUs convert to Common Stock on a one-for-one basis. Read SEC document |
| May 04, 2022 Filed May 6, 2022 22:32 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantStock Settled Appreciation Rights · Derivative | 53,364 | $0.00 Strike: $126.49 | $0.00 |
DisclosureSEC source: 0001225208-22-006678 · doc4.xml · derivative · entry 2 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,364 Underlying: Common Stock · 53,364 shares Expires 2029-05-04 Read SEC document |
| May 04, 2022 Filed May 6, 2022 22:32 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 10,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006678 · doc4.xml · derivative · entry 1 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,673 Underlying: Common Stock · 10,673 shares Expires 2025-04-04 F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · shares: Represents RSUs granted under the Equity Choice Program. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:19 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantStock Settled Appreciation Rights · Derivative | 29,613 | $0.00 Strike: $128.41 | $0.00 |
DisclosureSEC source: 0001225208-22-004197 · doc4.xml · derivative · entry 3 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,613 Underlying: Common Stock · 29,613 shares Expires 2029-03-01 F4 · shares: The Stock Settled Appreciation Rights will vest in three equal tranches on each of March 1, 2023, March 1, 2024, and March 1, 2025, in each case subject to the reporting person's continued employment with the Company. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:19 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 23,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-004197 · doc4.xml · derivative · entry 2 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,363 Underlying: Common Stock · 23,363 shares Expires 2025-03-01 F3 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:19 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Deferred Stock Units · Derivative | 6,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-004197 · doc4.xml · derivative · entry 1 Clyburn Frank · CIK 0001763963 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,619 Underlying: Common Stock · 6,619 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Restricted Stock Units ("DSUs") convert to Common Stock on a one-for-one basis. F2 · derivative.exercise_date: The DSUs will vest in five equal tranches on each of March 1, 2023, March 1, 2024, March 1, 2025, March 1, 2026, and March 1, 2027, in each case subject to the reporting person's continued employment with the Company. The DSUs are payable in Common Stock upon termination of employment. F2 · derivative.expiration_date: The DSUs will vest in five equal tranches on each of March 1, 2023, March 1, 2024, March 1, 2025, March 1, 2026, and March 1, 2027, in each case subject to the reporting person's continued employment with the Company. The DSUs are payable in Common Stock upon termination of employment. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,847 | $0.00 Strike: $56.49 | $0.00 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · derivative · entry 9 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,848 Underlying: Common Stock · 19,847 shares Expires 2024-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2015, 5/2/2016, and 5/2/2017. F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,915 | $0.00 Strike: $43.65 | $0.00 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · derivative · entry 8 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,915 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 39,762 | $87.87 | $3,493,878.99 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 5 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,095.087 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.8000 to $87.8950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,857.087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 3 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,010.087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · derivative · entry 7 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,358 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 30, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,162 | $88.05 | $102,314.10 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,095.087 Read SEC document |
| October 30, 2021 Filed Nov 2, 2021 22:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,358 | $88.05 | $207,621.90 |
DisclosureSEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,257.087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,324 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001127602-21-016201 · form4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,323 Underlying: Common Stock · 19,324 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 19,324 | $78.32 | $1,513,440.22 |
DisclosureSEC source: 0001127602-21-016201 · form4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348.057 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $78.42, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 10, 2021 Filed May 11, 2021 18:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016201 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,672.057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015744 · form4.xml · derivative · entry 5 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,906 shares Expires 2021-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 131,633 | $0.00 Strike: $75.99 | $0.00 |
DisclosureSEC source: 0001127602-21-015744 · form4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,633 Underlying: Common Stock · 131,633 shares Expires 2031-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 939 | $75.98 | $71,345.22 |
DisclosureSEC source: 0001127602-21-015744 · form4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348.057 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,906 | $75.98 | $144,817.88 |
DisclosureSEC source: 0001127602-21-015744 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,287.057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed Nov 4, 2021 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 39,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028389 · form4.xml · derivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,479 Underlying: Common Stock · 39,479 shares Expires 2024-05-04 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in one installment on 5/4/2024. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:12 UTC | DuPont de Nemours, Inc. DD · Entity 3297 | GrantCommon Stock | 2,207 | $77.05 | $170,049.35 |
DisclosureSEC source: 0001666700-21-000027 · edgar.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,034.4895 F1 · balance_after: Includes acquisition of shares pursuant to dividend reinvestment. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 9,432 | $72.62 | $684,951.84 |
DisclosureSEC source: 0001127602-21-008569 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,588.769 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028036 · form4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,288 Underlying: Common Stock · 2,287 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,137 | $75.89 | $86,286.93 |
DisclosureSEC source: 0001127602-20-028036 · form4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,518.801 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,287 | $75.89 | $173,560.43 |
DisclosureSEC source: 0001127602-20-028036 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,655.801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,876 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001127602-20-023070 · form4.xml · derivative · entry 4 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,876 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 18,876 | $81.55 | $1,539,273.62 |
DisclosureSEC source: 0001127602-20-023070 · form4.xml · nonDerivative · entry 2 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,763.106 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.5400 to $81.5550, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 18,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023070 · form4.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,639.106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:20 UTC | DuPont de Nemours, Inc. DD · Entity 3297 | GrantCommon Stock | 3,438 | $49.46 | $170,043.48 |
DisclosureSEC source: 0001666700-20-000026 · edgar.xml · nonDerivative · entry 1 Clyburn Frank · CIK 0001763963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,717.3423 F1 · balance_after: Includes acquisition of shares pursuant to dividend reinvestment. Read SEC document |
| May 05, 2020 Filed May 6, 2020 21:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 3,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015658 · form4.xml · derivative · entry 7 Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,752 shares Expires 2020-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.